knowledge -WSS

knowledge

author：explore 2025-09-27 22:59:53 - browse：75924

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Connecting traumatic brain injury and domestic violence

entertainment

WSS

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

The best solution to the drug shortages problem

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Can food be medicine? And other questions about a new push

Friends ask where James Watson's attitudes about race came from

leisure time

knowledge

leisure time

Drug repurposing or repositioning? The language matters

Meta looks to target Twitter with a rival app called Threads

Malaria cases in Florida and Texas: Here’s what you need to know

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

BioMarin wins approval for gene therapy to treat hemophilia A

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

How to save PrEP access — and even expand it

What to know about Virgin Galactic's 1st mission taking paying customers to space

Moonlake's readout produced a cash windfall. Risks remain

Did the public have the right to know Arthur Ashe had AIDS?

focus

What to know about Virgin Galactic's 1st mission taking paying customers to space

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Wegovy trial has doctors encouraged over new possibilities

7 people shot in DC, police say

New case study details death in closely watched Alzhiemer's trial

Drastic changes should bring profitability, startup health insurers say

leisure time

knowledge

entertainment

entertainment